跳至主要内容
临床试验/ISRCTN37397692
ISRCTN37397692已完成未知

Collection of white blood cells [using leukapheresis] from rheumatoid arthritis patients for the validation of an advanced treatment for rheumatoid arthritis (tolDC)

ewcastle upon Tyne Hospitals NHS Foundation Trust0 个研究点目标入组 6 人开始时间: 2021年4月13日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • 1. ACPA positive RA based on local NHS laboratory cut-off. If ACPA titre is <3 times laboratory upper limit of normal, patients must also be RF positive based on local NHS laboratory cut-off
  • 2. Age 18 years or over
  • 3. Ability to provide written informed consent
  • 4. Receiving methotrexate, either as monotherapy or in combination with additional conventional synthetic disease modifying drug(s) (csDMARDs) at a stable dose for at least 4 weeks prior to screening
  • 5. At least 6 months since diagnosis of RA
  • 6. ACR Functional Class I-III
  • 7. Active disease – DAS 28 >3.2

排除标准

  • 1. Use of investigational medicinal products within 30 days prior to screening date
  • 2. Receiving biologic DMARD or targeted synthetic DMARD (tsDMARD)
  • 3. Receiving glucocorticoids by any route accept topical/inhaled within 4 weeks of screening (nasal spray permitted)
  • 4. Receiving non-steroidal anti-inflammatory drugs (NSAID) at an unstable dose. Patients may be receiving NSAID prior to screening, provided the dose has been stable for at least 4 weeks prior to screening.
  • 5. Serious or unstable co-morbidity deemed unsuitable by PI, eg. COPD, cardiac failure
  • 6. Any known medical condition or contra-indication to leukapheresis, e.g. positive serology screen for hepatitis B or C, HIV infections
  • 7. History of hepatitis B or C, syphilis, HIV, CMV or HTLV-1/2 infections
  • 8. History of recurrent or chronic infection
  • 9. Pregnancy, or women planning to become pregnant within the study period, or women who are breast feeding
  • 10. Known hypersensitivity to local or systemic corticosteroid therapy or local anaesthetic
  • 11. Poor venous access or medical condition precluding leukapheresis
  • 12. Infection requiring hospitalization or IV antibiotics within 6 weeks of leukapheresis procedure
  • 13. Immunization with live vaccine within 6 weeks of leukapheresis procedure
  • 14. Anaemia defined as Hb<10g/dL; neutrophils< 2.00 x109/L; platelets <150x109/L
  • 15. Known active infection at screening visit or at screening (except fungal nail infection)

研究者

发起方
ewcastle upon Tyne Hospitals NHS Foundation Trust

相似试验

Validation of advanced treatment for rheumatoid... | 临床试验